LICITRA, LISA FRANCESCA LINDA
LICITRA, LISA FRANCESCA LINDA
Dipartimento di Oncologia ed Emato-Oncologia
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 D. Rischin, A. R Hansen, E.E. W Cohen, M. Tahara, K. J Harrington, R. I Haddad, L. Licitra, H. Mehanna, R. L Ferris, P. Koralewski
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025 P. Mccoon, Y. Wang, Z. Lai, Q. Zhang, W. Li, S. Wildsmith, N. Morsli, R. Raja, N. Holoweckyj, J. Walker, M. De Los Reyes, R. Mesia, L. Licitra, R.L. Ferris, J. Fayette, D.P. Zandberg, L.L. Siu, R. Haddad
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 J. Fayette, L. Licitra, K. Harrington, R. Haddad, L.L. Siu, Y.-. Liu, M. Tahara, J.-. Machiels, D. Rischin, T.Y. Seiwert, R.L. Ferris, U. Keilholz, A. Psyrri, B. Keam, P. Bossi, R. Metcalf, C.-. Hsieh, P.M.J. Clement, P. Isaev, A. Mudunov, J. Dinis, A. Hoeben, S. Kasper, K. Klinghammer, M. Hwang, J. Blando, O. Serrano, D. Ruscica, R.B. Cohen
The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2
2025 P. Rondi, D. Mattavelli, V. Rampinelli, A. Schreiber, E. Orlandi, B. Vischioni, N.A. Iacovelli, G. Calareso, C. Bergamini, S. Alfieri, P. Castelnuovo, P. Battaglia, M. Turri-Zanoni, P. Nicolai, M. Ferrari, L. Licitra, P. Bossi, D. Farina, M. Ravanelli, C. Resteghini
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
2025 E. Colombo, M. Ducceschi, S. Cavalieri, M. Polignano, M. Bini, P. Ambrosini, M. De Monte, G. Montelatici, A. Russo, V. Bellia, S. Bhoori, C. Bergamini, S. Alfieri, I. Nuzzolese, A. Ottini, V. Mazzaferro, F. Raspagliesi, L. Licitra, M. Mantiero
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck
2025 P. Szturz, T. Fuereder, Y. Guo, L. Licitra, R. Mesia, P. Ivanyi, A. Falco, M. Tahara, M.-. Solbes, F. Venturini, P. Bossi
The chemo-free approach for PDL1-positive platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma: Viable option or misguided myth?
2025 S. Cavalieri, N. Crippa, B. Lombardi Stocchetti, L. Licitra
Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F.J.P. Hoebers, T. Poli, K. Scheckenbach, N.A. Iacovelli, M. Franceschini, E. Orlandi, L. Licitra, L. De Cecco
Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F. Hoebers, K. Scheckenbach, T.K. Hoffmann, D. Mattavelli, T. Poli, E. Orlandi, L. Licitra, L. De Cecco
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
2025 S. Alfieri, R. Romano, S. Marceglia, C. Sciortino, W. Ferrari Bravo, M. Zucchini, M.L. Piscitelli, I. Nuzzolese, S. Cavalieri, C. Bergamini, E. Colombo, A. Ottini, L. De Cecco, D. Lenoci, N.A. Iacovelli, M. Guzzo, E. Orlandi, L.D. Locati, P. Bossi, L. Licitra, F. Taverna
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study
2025 S. Rota, S. Buriolla, A. Franza, S. Cavalieri, C. Bergamini, S. Alfieri, I. Nuzzolese, E. Colombo, A. Ottini, B. Lombardi Stocchetti, G. Massa, A. Caraceni, L. Licitra, C. Resteghini
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial
2025 P. Bossi, A. Alberti, C. Bergamini, C. Resteghini, L.D. Locati, S. Alfieri, S. Cavalieri, E. Colombo, C. Gurizzan, L. Lorini, V. Tovazzi, M. Zamparini, M. Ravanelli, P.A. Ascierto, V. Rampinelli, A. Grammatica, R. Patuzzo, A. Maurichi, L.F. Licitra
Indirect comparison ofTPF and GP induction chemotherapy regimens in nasopharyngeal carcinoma: a data-driven reassessment before the transition to induction chemoimmunotherapy
2025 S. Cavalieri, A. Ottini, B.L. Stocchetti, L. Licitra
The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies
2025 I. Nuzzolese, S. Cavalieri, L.F. Licitra, S. Alfieri
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
2025 D. Lenoci, M.S. Serafini, M. Lucchetta, S. Cavalieri, R.H. Brakenhoff, F. Hoebers, K. Scheckenbach, T. Poli, L. Licitra, L. De Cecco
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma
2025 A. Corti, D. Lenoci, V.D.A. Corino, D. Mattavelli, M. Ravanelli, T. Poli, S. Cavalieri, L. Licitra, L. De Cecco, L. Mainardi
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
2025 J.-. Machiels, Y. Tao, L. Licitra, B. Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P.F. Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, S. Laban, R. Greil, M. Burian, M. Hetnal, J.-. Delord, R. Mesia, M. Taberna, J. Waldron, C. Simon, V. Gregoire, K. Harrington, C.M. Black, J.M. Norquist, A. Wang, B. Gumuscu, B. Bidadiand, L.L. Siu
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
2025 R. Galot, C. Le Tourneau, L. Licitra, J. Guigay, A. Kong, I. Tinhofer, C. Even, A. Daste, S. Henry, C. Borel, C. Abdeddaim, E. Seront, J.B. Prevost, A. Rutten, E. Saada-Bouzid, F. Rolland, P. Bonomo, M. Rasschaert, L. Dirix, C. Olungu, K. Tsechilidou, A.S. Govaerts, C. Fortpied, A. Joaquim, J.P. Machiels
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials
2025 C. Gurizzan, M. Cinquini, L. Legramandi, C. Resteghini, M. Siano, C. Bergamini, L. Lorini, D. Smussi, A. Paderno, L. Licitra, P. Bossi
Gender Diversity in the Middle Management Matters: Examining Gender Metrics for Organizational and Sustainable Success
2025 A.D. Chiaramonte, C. Marazzi, D. Terruzzin, L. Anemoni, A. Mereghetti, E. Orlandi, L. Licitra